European Regulators Clear Kowa's Superstatin Livalo; Drug Sales Estimated To Reach ¥50 Billion
This article was originally published in PharmAsia News
Executive Summary
Nagoya-based Kowa Pharmaceutical obtained European approval July 21 for Livalo (pitavastatin) for patients with high cholesterol